Summary: A large US study indicates that symptomatic infection with herpes simplex virus 1 (HSV-1)—commonly known for causing cold sores—may substantially increase the likelihood of being diagnosed with Alzheimer’s disease. The researchers report that people with a recorded HSV-1 diagnosis were about 80% more likely to have Alzheimer’s, while those treated with antiviral medications after an HSV-1 diagnosis had an approximately 17% lower risk.
These results align with growing evidence that HSV-1 can trigger inflammatory responses and promote accumulation of amyloid-beta in the brain—two processes central to Alzheimer’s pathology. Because the study is observational, it does not prove cause and effect, but it does strengthen the case for further research into antiviral therapies and public health measures aimed at preventing or treating herpesvirus infections.
Key findings
- Elevated risk: Individuals with a recorded HSV-1 diagnosis had an 80% higher likelihood of Alzheimer’s disease after adjusting for confounders.
- Potential protective effect: Among people with HSV-1, those treated with antiherpetic medications after diagnosis were around 17% less likely to develop Alzheimer’s than untreated individuals.
- Biological plausibility: HSV-1 and other neurotropic herpesviruses are implicated in brain inflammation and amyloid-beta deposition, mechanisms that could contribute to dementia.
Study background and methods
The study, funded by industry and published in BMJ Open, used a large US administrative claims database (IQVIA PharMetrics Plus) spanning 2006–2021 to examine links between herpesvirus infections and Alzheimer’s disease. Researchers matched people diagnosed with Alzheimer’s to controls without neurological disease by age, sex, geographic region, year of database entry, and number of healthcare visits, producing 344,628 matched case–control pairs.
The Alzheimer’s group was predominantly female (about 65%), with an average age of 73 and a higher burden of coexisting conditions—recognized risk factors for dementia. Within the dataset, 1,507 people with Alzheimer’s (0.44%) had a documented HSV-1 diagnosis compared with 823 (0.24%) in the matched control group. After adjusting for potentially influential variables, the association between HSV-1 diagnosis and Alzheimer’s remained strong.
Treatment patterns and outcomes
Among the 2,330 people identified with a history of HSV-1 infection in the dataset, 931 (40%) received antiherpetic medication following their diagnosis. Those who were treated had a lower observed risk of subsequent Alzheimer’s disease—approximately 17% lower—than those who did not receive antiviral therapy. The authors interpret this as suggestive that antiherpetic treatment could modify dementia risk, while noting that randomized clinical trials would be needed to confirm causality.
Other herpesviruses
The study also assessed other herpesviruses. Both HSV-2 and varicella zoster virus infections showed associations with increased Alzheimer’s risk in the analyses, indicating that several neurotropic herpesviruses may be relevant to dementia development.
Biological plausibility and mechanisms
The exact mechanisms by which HSV-1 or related viruses might increase dementia risk are not fully understood. The researchers point to evidence that HSV infection can induce inflammatory changes in the brain. In response to viral exposure, amyloid-beta (Aβ) peptides may be deposited as part of an innate immune response, potentially blocking viral fusion with cell membranes. These same peptides, however, are the primary component of amyloid plaques associated with Alzheimer’s disease. HSV-1 DNA has also been detected in Alzheimer’s plaques, and carriers of the ApoE ε4 allele—an established genetic risk factor for Alzheimer’s—may be more susceptible to herpesvirus infection.
Limitations
As an observational analysis of claims data, the study cannot confirm causation. The authors note potential sources of bias: prior HSV-1 infections occurring before patients entered the database would not be captured; many HSV-1 infections are asymptomatic and thus not recorded; and symptomatic individuals may not always seek care or receive a coded diagnosis. These factors could affect estimates of association.
Implications
Despite its limitations, the study adds to a growing body of research suggesting a link between herpesviruses and Alzheimer’s disease. The observed association between antiviral treatment and lower dementia risk supports the idea that antiviral strategies deserve further study, including prospective trials to evaluate whether antiviral therapy can reduce the incidence or progression of Alzheimer’s disease. The authors emphasize that preventing and managing herpesvirus infections may warrant greater attention as part of public health efforts to reduce dementia risk.
About this virology and Alzheimer’s disease research news
Author: Emma Dickinson
Source: BMJ
Contact: Emma Dickinson – BMJ
Image: The image is credited to Neuroscience News
Original Research: The findings are reported in BMJ Open